Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
Immunotherapy has shown great promise in the field of oncology, and recent clinical trials have illustrated that immune checkpoint blockade (ICB) is safe and effective at treating a range of tumor types. Cervical cancer (CC) is the fourth most common malignancy in women. However, first-line treatmen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1045481/full |
| _version_ | 1828085746903285760 |
|---|---|
| author | Zhuo Song Kun Zou Lijuan Zou |
| author_facet | Zhuo Song Kun Zou Lijuan Zou |
| author_sort | Zhuo Song |
| collection | DOAJ |
| description | Immunotherapy has shown great promise in the field of oncology, and recent clinical trials have illustrated that immune checkpoint blockade (ICB) is safe and effective at treating a range of tumor types. Cervical cancer (CC) is the fourth most common malignancy in women. However, first-line treatments for locally advanced cervical cancer (LACC) and recurrent/metastatic (R/M) CC have limited efficacy. Thus, it is necessary to explore new treatment approaches. The National Comprehensive Cancer Network (NCCN) currently recommends pembrolizumab, a programmed cell death protein 1 (PD-1) monoclonal antibody, as a first line therapy for individuals with R/M CC. This study reviews the progress of ICB therapy for LACC and R/M CC and describes the current status of the combination of ICB therapy and other therapeutic modalities, including radiotherapy, chemotherapy, targeted therapy, and other immunotherapies. The focus is placed on studies published since 2018 with the aim of highlighting novel CC-specific immunotherapeutic approaches and treatment targets. |
| first_indexed | 2024-04-11T04:44:24Z |
| format | Article |
| id | doaj.art-55fd7eee277844b7a264da831a4be0da |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T04:44:24Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-55fd7eee277844b7a264da831a4be0da2022-12-27T14:57:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.10454811045481Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical dataZhuo Song0Kun Zou1Lijuan Zou2Department of Radiation Oncology, The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Radiation Oncology, The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, ChinaImmunotherapy has shown great promise in the field of oncology, and recent clinical trials have illustrated that immune checkpoint blockade (ICB) is safe and effective at treating a range of tumor types. Cervical cancer (CC) is the fourth most common malignancy in women. However, first-line treatments for locally advanced cervical cancer (LACC) and recurrent/metastatic (R/M) CC have limited efficacy. Thus, it is necessary to explore new treatment approaches. The National Comprehensive Cancer Network (NCCN) currently recommends pembrolizumab, a programmed cell death protein 1 (PD-1) monoclonal antibody, as a first line therapy for individuals with R/M CC. This study reviews the progress of ICB therapy for LACC and R/M CC and describes the current status of the combination of ICB therapy and other therapeutic modalities, including radiotherapy, chemotherapy, targeted therapy, and other immunotherapies. The focus is placed on studies published since 2018 with the aim of highlighting novel CC-specific immunotherapeutic approaches and treatment targets.https://www.frontiersin.org/articles/10.3389/fonc.2022.1045481/fullcervical cancerimmunotherapylocally advancedrecurrent metastaticimmune checkpointprogrammed cell death protein 1 (PD-1) |
| spellingShingle | Zhuo Song Kun Zou Lijuan Zou Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data Frontiers in Oncology cervical cancer immunotherapy locally advanced recurrent metastatic immune checkpoint programmed cell death protein 1 (PD-1) |
| title | Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data |
| title_full | Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data |
| title_fullStr | Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data |
| title_full_unstemmed | Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data |
| title_short | Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data |
| title_sort | immune checkpoint blockade for locally advanced or recurrent metastatic cervical cancer an update on clinical data |
| topic | cervical cancer immunotherapy locally advanced recurrent metastatic immune checkpoint programmed cell death protein 1 (PD-1) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1045481/full |
| work_keys_str_mv | AT zhuosong immunecheckpointblockadeforlocallyadvancedorrecurrentmetastaticcervicalcanceranupdateonclinicaldata AT kunzou immunecheckpointblockadeforlocallyadvancedorrecurrentmetastaticcervicalcanceranupdateonclinicaldata AT lijuanzou immunecheckpointblockadeforlocallyadvancedorrecurrentmetastaticcervicalcanceranupdateonclinicaldata |